Page last updated: 2024-09-04

tipifarnib and Multiple Myeloma

tipifarnib has been researched along with Multiple Myeloma in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (85.71)	29.6817
2010's	2 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Almenara, JA; Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Venditti, CA	1
Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C	1
Beaupre, DM; Buzzeo, RW; Cuevas, J; Gabriel, M; Hazlehurst, LA; Mari, Y; Yanamandra, N	1
Amiot, M; Bataille, R; Harousseau, JL; Le Gouill, S; Pellat-Deceunynck, C; Rapp, MJ; Robillard, N	1
Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D	1
Ashihara, E; Fuchida, S; Fujita, N; Inaba, T; Matsubara, H; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R	1
Adjei, AA; Ahmann, G; Alsina, M; Belle, AN; Bruzek, LM; Cantor, AB; Dalton, WS; Djulbegovic, B; Fonseca, R; Gerbino, E; Greipp, PR; Kaufmann, SH; Overton, RM; Price-Troska, T; Sebti, SM; Sullivan, D; Wilson, EF; Wright, JJ	1
Beaupre, DM; Boise, LH; Cepero, E; Lichtenheld, MG; Obeng, EA	1
Iida, S	1
Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K	1
Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R	1
Ashihara, E; Fuchida, S; Inaba, T; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N	1
Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N	1

Reviews

1 review(s) available for tipifarnib and Multiple Myeloma

Article	Year
[Multiple myeloma: from molecular pathogenensis to the development of molecular targeting therapies]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:11 Topics: Antineoplastic Agents; Chromosomal Instability; Chromosome Deletion; Enzyme Inhibitors; Humans; Multiple Myeloma; Quinolones; Signal Transduction	2004

Trials

2 trial(s) available for tipifarnib and Multiple Myeloma

Article	Year
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, Mar-01, Volume: 101, Issue:5 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood, 2004, May-01, Volume: 103, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Carrier Proteins; Cell Survival; Disease Progression; DNA-Binding Proteins; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Phosphorylation; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; ras Proteins; Salvage Therapy; Signal Transduction; STAT3 Transcription Factor; Trans-Activators	2004

Article

Year

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

Blood, 2003, Mar-01, Volume: 101, Issue:5

Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

Blood, 2004, May-01, Volume: 103, Issue:9

Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Carrier Proteins; Cell Survival; Disease Progression; DNA-Binding Proteins; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Phosphorylation; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; ras Proteins; Salvage Therapy; Signal Transduction; STAT3 Transcription Factor; Trans-Activators

2004

Other Studies

11 other study(ies) available for tipifarnib and Multiple Myeloma

Article	Year
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood, 2008, Sep-15, Volume: 112, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Checkpoint Kinase 1; DNA Damage; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Protein Kinase Inhibitors; Protein Kinases; Quinolones; ras Proteins; Staurosporine; Xenograft Model Antitumor Assays	2008
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood, 2010, Dec-09, Volume: 116, Issue:24 Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination	2010
Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. The Journal of pharmacology and experimental therapeutics, 2011, Volume: 337, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Cell Membrane; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinolones; Tumor Cells, Cultured; U937 Cells	2011
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia, 2002, Volume: 16, Issue:9 Topics: Aged; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Cell Division; DNA-Binding Proteins; Enzyme Inhibitors; Farnesyltranstransferase; Female; Flow Cytometry; Humans; Interleukin-6; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Protein Prenylation; Quinolones; STAT3 Transcription Factor; Trans-Activators; Tumor Cells, Cultured	2002
Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood, 2003, Nov-01, Volume: 102, Issue:9 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Farnesyltranstransferase; Humans; Multiple Myeloma; Mutation; Quinolones; ras Proteins; Tumor Cells, Cultured	2003
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Molecular cancer therapeutics, 2004, Volume: 3, Issue:2 Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Caspase 9; Caspase Inhibitors; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Division; Cell Line, Tumor; Humans; Intracellular Membranes; Membrane Potentials; Membrane Proteins; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Prenylation; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Signal Transduction; Transcription Factor CHOP; Transcription Factors	2004
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood, 2005, Jun-15, Volume: 105, Issue:12 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles	2005
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16 Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin	2005
Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro. Leukemia & lymphoma, 2005, Volume: 46, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Humans; Multiple Myeloma; Quinolones; Tumor Cells, Cultured	2005
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-15, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured	2006
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2007